Sunday, June 21, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 462 of 1,261
  1. US 10471066

    Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists

    VTV THERAPEUTICS LLC · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  2. US 10471035

    Compositions and methods for using esters of meroterpenes and of other resveratrol analogues

    Sunny BioDiscovery · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  3. US 10472387

    Inhibitors of glucocorticoid receptor

    ORIC PHARMACEUTICALS, INC. · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  4. US 2019337950

    BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS

    BIAL PORTELA & Cª S A [PT] · Granted Nov 7, 2019 · Expires Nov 2, 2039

    granted
  5. US 10465004

    Frizzled receptor antibodies for treatment of cancer

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  6. US 10464994

    Recombinant clusterin and use thereof in the treatment and prevention of disease

    The Board of Regents of the University of Texas System · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  7. US 10463652

    Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof

    VTV THERAPEUTICS LLC · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  8. US 10463697

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  9. US 10463748

    Human antibodies to S. aureus Hemolysin A toxin

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  10. US 10464989

    Polypeptides, cells, and methods involving engineered CD16

    Regents of the University of Minnesota · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  11. US 10465227

    Microbial testing devices, methods of making microbial testing devices and methods of identifying novel antimicrobial drug candidates

    The Board of Regents of the University of Texas System · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  12. US 10466249

    Methods and reagents for analyzing protein-protein interfaces

    Revolution Medicines, Inc. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  13. US 10465194

    Complement component iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  14. US 10464993

    Compositions and methods for immunomodulation in an organism

    UNIVERSITY OF CONNECTICUT · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  15. US 10464970

    Compounds that bind to human immunodeficiency virus rev response element

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  16. US 10464983

    Variants of adrenomedullin and calcitonin gene-related peptide and methods of use

    The Board of Regents of the University of Oklahoma · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  17. US 10463736

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  18. US 10463684

    Nucleobase analogue derivatives and their applications

    The Board of Regents of the University of Texas System · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  19. US 10463663

    Pyridazinone compounds and their use as DAAO inhibitors

    Takeda Pharmaceutical Company Limited · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  20. US 10463654

    Combination therapies for treating cancer

    RedHill Biopharma Ltd. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  21. US 10463674

    Process for manufacturing sterile ophthalmic pharmaceutical suspensions

    SENTISS PHARMA PRIVATE LIMITED · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  22. US 10464992

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  23. US 10463655

    Method of treatment with tradipitant

    VANDA PHARMACEUTICALS INC. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  24. US 10463659

    Multi-arm polymer prodrugs

    Nektar Therapeutics · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.